Download PDF
Drug Res (Stuttg) 2022; 72(07): 404-411
DOI: 10.1055/a-1840-3199
Original Article

Evaluation of Biological Activity of a Diazocine Derivative against Heart Failure Using an Ischemia-Reperfusion Injury Model

Figueroa-Valverde Lauro
1   Laboratory of Pharmaco-Chemistry, Faculty of Chemical Biological Sciences, University Autonomous of Campeche, Campeche, México
,
Rosas-Nexticapa Marcela
2   Facultad de Nutrición, Universidad Veracruzana, Médicos y Odontologos s/n, Unidad del Bosque, Veracruz, México
,
López-Ramos Maria
1   Laboratory of Pharmaco-Chemistry, Faculty of Chemical Biological Sciences, University Autonomous of Campeche, Campeche, México
,
Alvarez-Ramirez Magdalena
2   Facultad de Nutrición, Universidad Veracruzana, Médicos y Odontologos s/n, Unidad del Bosque, Veracruz, México
,
Mateu-Armad Maria Virginia
2   Facultad de Nutrición, Universidad Veracruzana, Médicos y Odontologos s/n, Unidad del Bosque, Veracruz, México
,
Díaz-Cedillo Francisco
3   Escuela Nacional de Ciencias Biológicas del Instituto Politécnico Nacional, Santo Tomas, México
,
Garcimarrero-Espino Alejandra
2   Facultad de Nutrición, Universidad Veracruzana, Médicos y Odontologos s/n, Unidad del Bosque, Veracruz, México
,
Lopez Gutierrez Tomas
2   Facultad de Nutrición, Universidad Veracruzana, Médicos y Odontologos s/n, Unidad del Bosque, Veracruz, México
,
Melgarejo-Gutierrez Montserrat
4   Facultad de Medicina Universidad Veracruzana, Médicos y Odontologos s/n, Unidad del Bosque, Veracruz, México
› Author Affiliations
› Further Information
Also available at
    Permissions and Reprints

Abstract

Background There are studies, which suggest that some diazocine derivatives can exert effects on the cardiovascular system; however, these effects are not very clear.

Objective The aim of this research was to evaluate the biological activity of a diazocine derivative against heart failure translated as area infarct.

Methods Biological activity produced by diazocine derivatives against heart failure was determinate using an ischemia/reperfusion injury model. Besides, to characterize the molecular mechanism of effect exerted by diazocine derivative on left ventricular pressure (LVP) was determinate in an isolated rat heart model using nifedipine, PINAME TXA2, and quinalizarin as controls.

Results The results showed that diazocine derivative decrease the infarct area and increase the LVP. However, the effect produced by diazocine derivative on LVP was inhibited in the presence of quinalizarin.

Conclusions The results indicate that biological activity produced by diazocine derivative on left ventricular pressure is through protein CK2 activation; this phenomenon could be translated as a decrease in both infarct area and heart failure.

Key words

Diazocine - infarct area - heart failure - protein CK2


Publication History

Received: 06 April 2022

Accepted: 25 April 2022

Article published online:
20 June 2022

© 2022. Thieme. All rights reserved.

Georg Thieme Verlag
Rüdigerstraße 14, 70469 Stuttgart, Germany

 

  • References

  • 1 Huang Y, Liao J, Wang W, Liu H, Guo H. Synthesis of heterocyclic compounds through nucleophilic phosphine catalysis. Chem Comm 2020; 56: 15235-15281
    CrossrefPubMedGoogle Scholar
  • 2 Zhao P, Yu X, Zhou Y, Huang C, Wu Y, Zhu Y, Wu A. Arylacetylenes as two-carbon synthons: synthesis of eight-membered rings via C [triple bond, length as m-dash] C bond cleavage. Chem Comm 2020; 56: 12554-12557
    CrossrefPubMedGoogle Scholar
  • 3 Vitaku E, Smith D, Njardarson J. Analysis of the structural diversity, substitution patterns, and frequency of nitrogen heterocycles among US FDA approved pharmaceuticals: miniperspective. J Med Chem 2014; 57: 10257-10274
    CrossrefPubMedGoogle Scholar
  • 4 Arnold L, Luo W, Guy R. Synthesis of medium ring heterocycles using an intramolecular Heck reaction. Org Lett 2004; 6: 3005-3007
    CrossrefPubMedGoogle Scholar
  • 5 Barraclough P, Beams R, Black J. Cambridge D, Collard D, Demaine D, Whiting M. Inotropic activity of heterocyclic analogues of isomazole. Eur J Med Chem 1990; 25: 467-477
    CrossrefPubMedGoogle Scholar
  • 6 Jonas R, Klockow M, Lues I, Pruecher H, Schliep H, Wurziger H. Synthesis and biological activities of meribendan and related heterocyclic benzimidazolo-pyridazinones. Eur J Med Chem 1993; 28: 129-140
    CrossrefPubMedGoogle Scholar
  • 7 Davey D, Erhardt P, Lumma W, Wiggins J, Sullivan M, Pang D, Cantor E. Cardiotonic agents. 1. Novel 8-aryl substituted imidazo [1, 2-a]-and-[1, 5-a] pyridines and imidazo [1, 5-a] pyridinones as potential positive inotropic agents. J Med Chem 1987; 30: 1337-1342
    CrossrefPubMedGoogle Scholar
  • 8 Yammazaki H, Harada H, Matsuzaki K, Yoshioka K, Takase M, Ohki E. Studies on Bi-heterocyclic Compounds. II.: 5-Substituted Thiazolones. Chem Pharm Bull 1990; 38: 45-48
    CrossrefPubMedGoogle Scholar
  • 9 Herold P, Herzig J, Wenk P, Leutert T, Zbinden P, Fuhrer W, Rihs G. 5-Methyl-6-phenyl-1, 3, 5, 6-tetrahydro-3, 6-methano-1, 5-benzodiazocine-2, 4-dione (BA 41899): representative of a novel class of purely calcium-sensitizing agents. J Med Chem 1995; 38: 2946-2954
    CrossrefPubMedGoogle Scholar
  • 10 Herzig S. Ca2+channel activation by CGP 48506, a new positive inotropic benzodiazocine derivative. Eur. J Pharm 1996; 295: 113-117
    PubMedGoogle Scholar
  • 11 Rosas-Nexticapa M, Figueroa-Valverde L, Díaz-Cedillo F, López-Ramos M, Mateu-Armad M, Alvarez-Ramirez M, Lopez-Gutierrez T, Benitez-Coeto L. Cauch-Carrillo R. Design and Synthesys of a New Diazazocine-5,8-dione using some chemical strategies. Heter Lett 2021; 11: 515-520
    PubMedGoogle Scholar
  • 12 Figueroa-Valverde L, Diaz-Cedillo F, Rosas-Nexticapa M, Pool-Gomez E, Lopez-Ramos M, Sarabia-Alcocer B, Damian-Hernandez I. Evaluation of activity exerted by a steroid derivative on injury by ischaemia/reperfusion. African J Pharm Pharmacol 2014; 8: 157-167
    CrossrefPubMedGoogle Scholar
  • 13 Figueroa-Valverde L, Diaz-Cedillo F, Camacho-Luis A, Garcia-Cervera E, Pool-Gomez E, Rosas-Nexticapa M, Sarao-Alvarez A. Activity induced by a progesterone derivative on injury by ischemia-reperfusion in an isolated heart model. African J Pharm Pharmacol 2013; 7: 1957-1968
    CrossrefPubMedGoogle Scholar
  • 14 Melgari D, Brack K, Zhang C, Zhang Y, El-Harchi A, Mitcheson J, Hancox J. hERG potassium channel blockade by the HCN channel inhibitor bradycardic agent ivabradine. J Am Heart Assoc 2015; 4: e001813
    CrossrefPubMedGoogle Scholar
  • 15 Richardt G, Blessing R, Schömig A. Cardiac noradrenaline release accelerates adenosine formation in the ischemic rat heart: role of neuronal noradrenaline carrier and adrenergic receptors. J Mol Cell Cardiol 1994; 26: 1321-1328
    CrossrefPubMedGoogle Scholar
  • 16 Kaheinen P, Pollesello P, Levijoki J, Haikala H. Effects of levosimendan and milrinone on oxygen consumption in isolated guinea-pig heart. J Cardiov Pharmacol 2004; 43: 555-561
    CrossrefPubMedGoogle Scholar
  • 17 Millar N. Biology statistics made simple using Excel. School. Sci Rev 2001; 83: 23-34
    PubMedGoogle Scholar
  • 18 Harden F, Brown L, Quinn R, Harrison G, Headrick J, Rose’Meyer R, Willis R. Study of the novel non-xanthine heterocyclic compound GU285 as a potent non-selective adenosine receptor antagonist in the rat. Arzneimittelforschung 2002; 52: 175-181
    PubMedGoogle Scholar
  • 19 Sato Y, Shimoji Y, Fujita H, Nishino H, Mizuno H, Kobayashi S, Kumakura S. Studies on cardiovascular agents. 6. Synthesis and coronary vasodilating and antihypertensive activities of 1, 2, 4-triazolo [1, 5-a] pyrimidines fused to heterocyclic systems. J Med Chem 1980; 23: 927-937
    CrossrefPubMedGoogle Scholar
  • 20 Garcia E, Figueroa L, Diaz F, Lopez M, Rosas M. Design and synthesis of new pirrol-indol derivative with positive inotropic activity. Oriental J Chem 2015; 31: 31-41
    CrossrefPubMedGoogle Scholar
  • 21 Sullivan M, Knight J, Higginbotham M, Cobb F. Relation between central and peripheral hemodynamics during exercise in patients with chronic heart failure. Muscle blood flow is reduced with maintenance of arterial perfusion pressure. Circulation 1989; 80: 769-781
    CrossrefPubMedGoogle Scholar
  • 22 Gregg D. Effect of coronary perfusion pressure or coronary flow on oxygen usage of the myocardium. Circulation Res 1963; 13: 497-500
    CrossrefPubMedGoogle Scholar
  • 23 Paradis N, Martin G, Rivers E, Goetting M, Appleton T, Feingold M, Nowak R. Coronary perfusion pressure and the return of spontaneous circulation in human cardiopulmonary resuscitation. J Am Med Assoc 1990; 263: 1106-1113
    CrossrefPubMedGoogle Scholar
  • 24 Sulfi S, Timmis A. Ivabradine – the first selective sinus node If channel inhibitor in the treatment of stable angina. International journal of clinical practice 2006; 60: 222-228
    CrossrefPubMedGoogle Scholar
  • 25 Toyoda S, Haruyama A, Inami S, Arikawa T, Saito F, Watanabe R, Inoue T. Effects of carvedilol vs bisoprolol on inflammation and oxidative stress in patients with chronic heart failure. J Cardiol 2020; 75: 140-147
    CrossrefPubMedGoogle Scholar
  • 26 Abulhasan Y, Jimenez J, Teitelbaum J, Simoneau G, Angle M. Milrinone for refractory cerebral vasospasm with delayed cerebral ischemia. J Neuros 2020; 1: 1-12
    CrossrefPubMedGoogle Scholar
  • 27 Masarone D, Valente F, Verrengia M, Ammendola E, Gravino R, D’Alterio G, Pacileo G. Efficacy and safety of repeated infusion of levosimendan in outpatients with advanced heart failure: a real-world experience. J Cardiovasc Med 2020; 21: 919-921
    CrossrefPubMedGoogle Scholar
  • 28 Winiarski J, Barros M, Wecker G, Nagurniak G, Parreira R, Affeldt R, Jost C. A novel hybrid organic – inorganic silsesquioxane and cobalt (ii) tetrasulphophthalocyanine material as an efficient electrochemical sensor for the simultaneous determination of the anti-hypertensive nifedipine and its metabolite. J Mat Chem 2020; 8: 6839-6850
    PubMedGoogle Scholar
  • 29 Asano T, Noda Y, Tanaka K, Yamakawa N, Wada M, Mashimo T, Takenaga M. A2B adenosine receptor inhibition by the dihydropyridine calcium channel blocker nifedipine involves colonic fluid secretion. Sci Rep 2020; 10: 1-12
    CrossrefPubMedGoogle Scholar
  • 30 Harris R, Black L, Surapaneni S, Kolasa T, Majest S, Namovic MT, Bell R. ABT-963 [2-(3, 4-difluoro-phenyl)-4-(3-hydroxy-3-methyl-butoxy)-5-(4-methanesulfonyl-phenyl)-2H-pyridazin-3-one], a highly potent and selective disubstituted pyridazinone cyclooxgenase-2 inhibitor. J Pharmacol Exp Ther 2004; 311: 904-912
    CrossrefPubMedGoogle Scholar
  • 31 Pressman B, Fahim M. Pharmacology and toxicology of the monovalent carboxylic ionophores. Annual Rev Pharmacol Toxicol 1982; 22: 465-490
    CrossrefPubMedGoogle Scholar
  • 32 Meena V, Meena D, Rathore P, Chaudhary S, Soni J. Comparison of the efficacy and safety of indomethacin, ibuprofen, and paracetamol in the closure of patent ductus arteriosus in preterm neonates – A randomized controlled trial. Annals Ped Cardiol 2020; 13: 130
    CrossrefPubMedGoogle Scholar
  • 33 Hanasaki K, Arita H. Characterization of a new compound, S-145, as a specific TXA2 receptor antagonist in platelets. Thrombosis Res 1988; 50: 365-376
    CrossrefPubMedGoogle Scholar
  • 34 Graciotti M, Alam M, Solyakov L, Schmid R, Burley G, Bottrill A, Tobin A. Malaria protein kinase CK2 (PfCK2) shows novel mechanisms of regulation. Plos One 2014; 9: 1-8
    CrossrefPubMedGoogle Scholar
  • 35 Singh N, Ramji D. Protein kinase CK2, An important regulator of the infammatory response?. J Mol Med 2008; 86: 887-897
    CrossrefPubMedGoogle Scholar
  • 36 Cozza G, Mazzorana M, Papinutto E, Bain J, Elliott M, Di-Maira G, Pinna L. Quinalizarin as a potent, selective and cell-permeable inhibitor of protein kinase CK2. Biochem J 2009; 421: 387-395
    CrossrefPubMedGoogle Scholar
  • 37 Zhou Y, Li K, Zhang S, Li Q, Li Z, Zhou F, Meng R. Quinalizarin, a specific CK2 inhibitor, reduces cell viability and suppresses migration and accelerates apoptosis in different human lung cancer cell lines. Indian J Cancer 2015; 52: 119
    CrossrefPubMedGoogle Scholar
  • 38 Cvan K, Grabnar I, Kerec M, Vovk T, Trontelj J, Anker S, Lainscak M. Bisoprolol pharmacokinetics and body composition in patients with chronic heart failure: a longitudinal study. Eur J Clin Pharmacol 2016; 72: 813-822
    CrossrefPubMedGoogle Scholar
  • 39 Ragueneau I, Laveille C, Jochemsen R, Resplandy G, Funck-Brentano C, Jaillon P. Pharmacokinetic-pharmacodynamic modeling of the effects of ivabradine, a direct sinus node inhibitor, on heart rate in healthy volunteers. Clin Pharmacol Ther 1998; 64: 192-203
    CrossrefPubMedGoogle Scholar
  • 40 Kates R, Leier C. Dobutamine pharmacokinetics in severe heart failure. Clin Pharmacol Ther 1978; 24: 537-541
    CrossrefPubMedGoogle Scholar
  • 41 Ramamoorthy C, Anderson G, Williams G, Lynn A. Pharmacokinetics and side effects of milrinone in infants and children after open heart surgery. Anesth Analg 1998; 86: 283-289
    CrossrefPubMedGoogle Scholar
  • 42 El-Kadi A, Zordoky B. Modulation of cardiac and hepatic cytochrome P450 enzymes during heart failure. Curr Drug Met 2008; 9: 122-128
    CrossrefPubMedGoogle Scholar
  • 43 Wessler J, Grip L, Mendell J, Giugliano P. The P-glycoprotein transport system and cardiovascular drugs. J Am Coll Cardiol 2013; 61: 2495-2502
    CrossrefPubMedGoogle Scholar
  • 44 Lagunin A, Gloriozova T, Dmitriev A, Volgina N. Poroikov V. Bull. Computer evaluation of drug interactions with P-glycoprotein. Exp Biol Med 2013; 154: 521-524
    CrossrefPubMedGoogle Scholar